Sudeep Pharma Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
SUDEEPPHRM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.4 pts more than Nifty Microcap 250 and 1.4 pts more than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Sudeep Pharma reported strong full-year results with consolidated revenue growing 28% to Rs. 64,226 lakhs (vs Rs. 50,200 lakhs in prior year). Profit after tax jumped 26% to Rs. 17,428 lakhs (vs Rs. 13,873 lakhs). The company completed its IPO in November 2025, raising Rs. 9,500 lakhs through fresh equity issue and Rs. 16,000 lakhs via CCPS. It also acquired Ireland-based Nutrition Supplies & Services (NSS) in May 2025 for Rs. 12,858 lakhs, resulting in provisional goodwill of Rs. 6,824 lakhs. The Board recommended a final dividend of Rs. 1.50 per share (150%). Statutory auditors BSR & Co issued an unmodified (clean) opinion on both standalone and consolidated results. Cash and cash equivalents stood at Rs. 2,674 lakhs at year end.
The stock delivered robust growth with 28% revenue increase and 26% PAT growth, driven by both pharma segments and the new specialty ingredients business from the NSS acquisition. The clean audit opinion and dividend payout signal financial health.